Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KB707 in advanced solid tumor malignancies affecting the lungs
NCT06228326Phase 2Recruiting
- Sponsor
- Krystal Biotech, Inc.
- Start
- Apr 2024
- Primary completion
- Feb 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of KB707 in lung cancer, sponsored by Krystal Biotech, Inc.. Started Apr 2024; status: recruiting.
02
Drugs
KB707
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT06228326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06228326.